Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Teva’s anti-IL-15 antibody showed encouraging 24-week results in a phase 1b vitiligo study, with 42% of patients achieving at least 50% facial improvement and 21% reaching 75% facial improvement.

The company also reported strong patient-reported improvements and no safety signals so far.

Teva believes the therapy could be differentiated by its long half-life and quarter-year dosing potential, with serum suppression lasting up to 80 to 90 days at the top dose.

Management highlighted it as a key part of the company’s shift toward a biopharma-focused growth strategy.

The company plans to start a phase 2 study this year after meeting with the FDA, and it sees potential for anti-IL-15 beyond vitiligo in conditions such as celiac disease and alopecia areata.

Teva said the vitiligo update is one of several major pipeline milestones expected in 2026.

Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.

During a conference call, President and CEO Richard Francis called the data “a milestone” in Teva’s “Pivot to Growth” plan and said 2026 is expected to include eight key events for the company, up from a prior expectation of seven following the addition of an ecopipam NDA filing.

Francis said Teva’s pipeline includes several programs that the company believes could each become $1 billion products in their respective indications, including anti-IL-15, duvakitug,...